Drug intelligence / Profile preview

MAQ-001

Development stage: Phase 1
Lead developer: MabQuest Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAQ-001 is a novel anti-PD-1 monoclonal antibody developed by MabQuest SA. It is designed to inhibit T cell exhaustion through an alternative mechanism that is independent of the conventional PD-1/PDL-1 blockade pathway. This investigational drug is being studied as a potential treatment for various advanced solid tumors, including cancers of the skin, lung, kidney, liver, stomach, bowel, female reproductive system, and hematology lymph nodes. It is being evaluated both as a monotherapy and in combination with ipilimumab.

Beyond the preview

Go deeper on MAQ-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAQ-001.

Explore the full profile